MX2017007826A - Proteina de fusion que conprende tres dominios de union a 5t4 y cd3. - Google Patents
Proteina de fusion que conprende tres dominios de union a 5t4 y cd3.Info
- Publication number
- MX2017007826A MX2017007826A MX2017007826A MX2017007826A MX2017007826A MX 2017007826 A MX2017007826 A MX 2017007826A MX 2017007826 A MX2017007826 A MX 2017007826A MX 2017007826 A MX2017007826 A MX 2017007826A MX 2017007826 A MX2017007826 A MX 2017007826A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- binding
- relates
- binding domains
- vector
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199493 | 2014-12-19 | ||
| PCT/EP2015/080795 WO2016097408A1 (en) | 2014-12-19 | 2015-12-21 | Fusion protein comprising three binding domains to 5t4 and cd3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007826A true MX2017007826A (es) | 2018-02-13 |
Family
ID=52282472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007826A MX2017007826A (es) | 2014-12-19 | 2015-12-21 | Proteina de fusion que conprende tres dominios de union a 5t4 y cd3. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10941207B2 (ko) |
| EP (1) | EP3233917B1 (ko) |
| JP (1) | JP6709003B2 (ko) |
| KR (1) | KR102495820B1 (ko) |
| CN (1) | CN107406509B (ko) |
| AU (1) | AU2015366166B2 (ko) |
| BR (1) | BR112017012910A2 (ko) |
| CA (1) | CA2970986C (ko) |
| GB (1) | GB2549632B (ko) |
| MX (1) | MX2017007826A (ko) |
| WO (1) | WO2016097408A1 (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| WO2018148445A1 (en) | 2017-02-08 | 2018-08-16 | Adimab, Llc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| JP7305549B2 (ja) * | 2017-04-05 | 2023-07-10 | エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド | ヒト化抗ｔｐｂｇ抗体およびその製造方法、その複合体および使用 |
| KR20200005732A (ko) | 2017-04-11 | 2020-01-16 | 인히브릭스, 인크. | 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법 |
| JP2020522474A (ja) * | 2017-05-23 | 2020-07-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
| US11845796B2 (en) | 2017-09-22 | 2023-12-19 | WuXi Biologics Ireland Limited | Bispecific polypeptide complexes |
| SG11202002508XA (en) | 2017-09-22 | 2020-04-29 | Wuxi Biologics Ireland Ltd | Novel bispecific cd3/cd19 polypeptide complexes |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| PE20210339A1 (es) * | 2018-03-12 | 2021-02-22 | Genmab As | Anticuerpos |
| CN113518647A (zh) * | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4028424A1 (en) * | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| WO2021247805A1 (en) * | 2020-06-05 | 2021-12-09 | The Johns Hopkins University | Humanized antibodies directed against kcnk9 |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| TW202405024A (zh) * | 2022-06-30 | 2024-02-01 | 日商凱依歐姆 生物科學股份有限公司 | 融合蛋白質 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CN101490085A (zh) | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| WO2012162561A2 (en) * | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CA2846432A1 (en) * | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
-
2015
- 2015-12-21 EP EP15817832.7A patent/EP3233917B1/en active Active
- 2015-12-21 KR KR1020177018818A patent/KR102495820B1/ko active IP Right Grant
- 2015-12-21 GB GB1709537.3A patent/GB2549632B/en active Active
- 2015-12-21 CA CA2970986A patent/CA2970986C/en active Active
- 2015-12-21 BR BR112017012910-8A patent/BR112017012910A2/pt not_active Application Discontinuation
- 2015-12-21 US US15/536,121 patent/US10941207B2/en active Active
- 2015-12-21 AU AU2015366166A patent/AU2015366166B2/en active Active
- 2015-12-21 JP JP2017532005A patent/JP6709003B2/ja active Active
- 2015-12-21 CN CN201580076505.9A patent/CN107406509B/zh active Active
- 2015-12-21 WO PCT/EP2015/080795 patent/WO2016097408A1/en active Application Filing
- 2015-12-21 MX MX2017007826A patent/MX2017007826A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2549632A (en) | 2017-10-25 |
| CA2970986C (en) | 2021-10-26 |
| EP3233917B1 (en) | 2024-04-17 |
| KR20170094319A (ko) | 2017-08-17 |
| AU2015366166B2 (en) | 2021-08-05 |
| JP6709003B2 (ja) | 2020-06-10 |
| WO2016097408A1 (en) | 2016-06-23 |
| CA2970986A1 (en) | 2016-06-23 |
| AU2015366166A1 (en) | 2017-06-29 |
| JP2018500025A (ja) | 2018-01-11 |
| US10941207B2 (en) | 2021-03-09 |
| BR112017012910A2 (pt) | 2018-02-06 |
| GB2549632A8 (en) | 2020-08-26 |
| KR102495820B1 (ko) | 2023-02-06 |
| GB201709537D0 (en) | 2017-08-02 |
| US20170342160A1 (en) | 2017-11-30 |
| EP3233917A1 (en) | 2017-10-25 |
| CN107406509A (zh) | 2017-11-28 |
| GB2549632B (en) | 2020-09-23 |
| CN107406509B (zh) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2549632A8 (en) | Fusion protein comprising three binding domains to 5T4 and CD3 | |
| PH12018500157A1 (en) | Antibody constructs for flt3 and cd3 | |
| PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
| MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
| PH12018500156A1 (en) | Antibody constructs for egfrviii and cd3 | |
| PH12015501651B1 (en) | Antibody constructs for cdh19 and cd3 | |
| PH12015501672A1 (en) | Binding molecules for bcma and cd3 | |
| MX2017001403A (es) | Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido. | |
| PH12018500241A1 (en) | Antibody constructs for dll3 and cd3 | |
| MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
| MX2017001401A (es) | Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas. | |
| TN2017000552A1 (en) | Antibody constructs for msln and cd3. | |
| TN2014000097A1 (en) | Binding molecules for bcma and cd3 | |
| EP4276116A3 (en) | Bispecific antibody constructs for cdh3 and cd3 |